Trial Profile
A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs BOS 172722 (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Boston Pharmaceuticals
- 14 Apr 2021 Status changed from active, no longer recruiting to completed.
- 25 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.
- 25 Nov 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.